Sandwich, United Kingdom

Enrico Colli

This inventor holds 1 USPTO granted patent. Top assignee: Warner Chilcott Company, LLC. Active years: 2014.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Enrico Colli: Innovator in Overactive Bladder Treatment

Introduction

Enrico Colli is a notable inventor based in Sandwich, GB. He has made significant contributions to the field of medicine, particularly in the treatment of overactive bladder conditions. His innovative work has led to the development of a specific medication aimed at alleviating patient discomfort.

Latest Patents

Enrico Colli holds a patent for the use of darifenacin in the treatment of urgency induced by overactive bladder. The invention provides the use of darifenacin, or a pharmaceutically acceptable derivative thereof, in the manufacture of a medicament for the reduction of urgency in patients suffering from this condition. This patent highlights his commitment to improving patient care and quality of life.

Career Highlights

Colli is associated with Warner Chilcott Company, LLC, where he has been instrumental in advancing pharmaceutical innovations. His work has not only contributed to the company's portfolio but has also had a positive impact on the healthcare industry.

Collaborations

Enrico has collaborated with notable colleagues such as Dzelal Serdarevic and Larence Howard Skillern. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Enrico Colli's contributions to the field of medicine, particularly through his patent on darifenacin, demonstrate his dedication to addressing urgent healthcare needs. His work continues to influence the treatment of overactive bladder, showcasing the importance of innovation in improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…